EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudie

Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation

Enrico Poletti, Matti Adam, Hendrik Wienemann, Antonio Sisinni, Kush P Patel, Ignacio J Amat-Santos, Mateusz Orzalkiewicz, Francesco Saia, Damiano Regazzoli, Claudia Fiorina, Vasileios Panoulas, Christina Brinkmann und 14 weitere

JACC: Cardiovascular Interventions · 2024-07 · 17 (13) · 1597-1606

DOI: 10.1016/j.jcin.2024.05.019 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2024-07. Verfasst von Enrico Poletti und 25 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy. Hauptthemen laut MEDLINE: Aortic Valve Insufficiency, Registries, Heart Valve Prosthesis, Aortic Valve. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Severe pure aortic regurgitation (AR) carries a high mortality and morbidity risk, and it is often undertreated because of the inherent surgical risk. Transcatheter heart valves (THVs) have been used off-label in this setting with overall suboptimal results. The dedicated "purpose-built" Jena Valve Trilogy (JVT, JenaValve Technology) showed an encouraging performance, although it has never been compared to other THVs. OBJECTIVES: The aim of our study was to assess the performance of the latest iteration of THVs used off-label in comparison to the purpose-built JVT in inoperable patients with severe AR. METHODS: We performed a multicenter, retrospective registry with 18 participating centers worldwide collecting data on inoperable patients with severe AR of the native valve. A bicuspid aortic valve was the main exclusion criterion. The primary endpoints were technical and device success, 1-year all-cause mortality, and the composite of 1-year mortality and the heart failure rehospitalization rate. RESULTS: Overall, 256 patients were enrolled. THVs used off-label were used in 168 cases (66%), whereas JVT was used in 88 (34%). JVT had higher technical (81% vs 98%; P < 0.001) and device success rates (73% vs 95%; P < 0.001), primarily driven by significantly lower incidences of THV embolization (15% vs 1.1%; P < 0.001), the need for a second valve (11% vs 1.1%; P = 0.004), and moderate residual AR (10% vs 1.1%; P = 0.007). The permanent pacemaker implantation rate was comparable and elevated for both groups (22% vs 24%; P = 0.70). Finally, no significant difference was observed at the 1-year follow-up in terms of mortality (HR: 0.99; P = 0.980) and the composite endpoint (HR: 1.5; P = 0.355). CONCLUSIONS: The JVT platform has a better acute performance than other THVs when used off-label for inoperable patients with severe AR. A longer follow-up is conceivably needed to detect a possible impact on prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aortic Valve InsufficiencyRegistriesHeart Valve ProsthesisAortic ValveTranscatheter Aortic Valve ReplacementProsthesis DesignSeverity of Illness IndexHumansFemaleMaleRetrospective StudiesAgedTreatment OutcomeAged, 80 and overRisk FactorsTime FactorsPatient ReadmissionRecovery of FunctionEuropeHeart FailureHemodynamics

Stichwörter der Autor:innen

JenaValve Trilogydedicated devicepure native aortic regurgitationtranscatheter aortic valve replacement

Autor:innen und Institutionen

  • IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy.
  • Department of Internal Medicine III-Cardiology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, United Kingdom.
  • Instituto de Ciencias Del Corazón, Hospital Clínico Universitario de Valladolid, Valladolid, Spain.
  • Cardiology Unit, Cardio-Thoracic-Vascular Department, IRCCS University Hospital of Bologna, Bologna, Italy.
  • Cardio Center, IRCCS Humanitas Research Hospital, Rozzano-Milan, Italy.

Zitieren

APA

Poletti, E., Adam, M., Wienemann, H., Sisinni, A., Patel, K. P., Amat-Santos, I. J., Orzalkiewicz, M., Saia, F., Regazzoli, D., Fiorina, C., Panoulas, V., Brinkmann, C., Giordano, A., Taramasso, M., Maisano, F., Barbanti, M., De Backer, O., Van Mieghem, N. M., Latib, A., …, & Testa, L. (2024). Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation. JACC: Cardiovascular Interventions, 17(13), 1597-1606. https://doi.org/10.1016/j.jcin.2024.05.019

Vancouver

Poletti E, Adam M, Wienemann H, Sisinni A, Patel KP, Amat-Santos IJ, et al. Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation. JACC: Cardiovascular Interventions. 2024;17(13):1597-1606. doi:10.1016/j.jcin.2024.05.019

BibTeX
@article{Poletti2024,
  author = {Poletti, Enrico and Adam, Matti and Wienemann, Hendrik and Sisinni, Antonio and Patel, Kush P and Amat-Santos, Ignacio J and Orzalkiewicz, Mateusz and Saia, Francesco and Regazzoli, Damiano and Fiorina, Claudia and Panoulas, Vasileios and Brinkmann, Christina and Giordano, Arturo and Taramasso, Maurizio and Maisano, Francesco and Barbanti, Marco and De Backer, Ole and Van Mieghem, Nicolas M and Latib, Azeem and Squillace, Mattia and Baldus, Stephan and Geyer, Martin and Baumbach, Andreas and Bedogni, Francesco and Rudolph, Tanja K and Testa, Luca},
  title = {Performance of Purpose-Built vs Off-Label Transcatheter Devices for Aortic Regurgitation},
  journal = {JACC: Cardiovascular Interventions},
  year = {2024},
  volume = {17},
  number = {13},
  pages = {1597--1606},
  doi = {10.1016/j.jcin.2024.05.019}
}
Kostenlos starten →